Search results for "IRI"

showing 10 items of 12514 documents

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell l…

2006

Superiority of irinotecan/cisplatin over etoposide/cisplatin was suggested in small-cell lung cancer (SCLC). This trial investigated irinotecan/carboplatin (IP) versus etoposide/carboplatin (EP).The interim analysis at the phase II/phase III transition point of the multicenter trial is reported. Extensive disease SCLC patients were randomized to receive carboplatin AUC 5 mg x min/ml either in combination with 50 mg/m2 of irinotecan on days 1, 8 and 15 (IP) or with etoposide 140 mg/m2 days 1-3 (EP). The primary end point was response rate and the secondary end points were toxicity and progression-free survival.Seventy patients were randomized. Significant differences in grade 3 and 4 thrombo…

AdultMalemedicine.medical_specialtyLung NeoplasmsPhases of clinical researchNeutropeniaIrinotecanGastroenterologyCarboplatinchemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalCarcinoma Small CellLung cancerEtoposideAgedEtoposideCisplatinbusiness.industryHematologyMiddle Agedmedicine.diseaseCarboplatinSurgeryIrinotecanOncologychemistryCamptothecinFemalebusinessmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent.

1998

A decreased basal and/or stimulated activity of the G-protein/adenylyl cyclase (AC) system in peripheral blood cells has been proposed to represent a trait marker for alcoholism. However, AC activity may underlie state-dependent changes, which may impair a proper interpretation of AC activity measurements. Our study examined systematically the AC activity in peripheral lymphocytes of 73 male alcohol-dependent patients (according to DSM-IV criteria) at three different time points of measurement during the clinical course of detoxification (day 0 = at admission, while still ethanol-affected; day 2 = at the presumed peak of withdrawal symptoms; day E = after detoxification). Basal and stimulat…

AdultMalemedicine.medical_specialtyLymphocyteGTPgammaSMedicine (miscellaneous)ToxicologyAdenylyl cyclaseAlcohol Withdrawal Deliriumchemistry.chemical_compoundBasal (phylogenetics)Reference ValuesInternal medicineDetoxificationmedicineHumansLymphocytesAgedForskolinbusiness.industryMiddle AgedPeripheralPsychiatry and Mental healthAlcoholismmedicine.anatomical_structureEndocrinologychemistryToxicitybusinessBiomarkersAdenylyl CyclasesAlcoholism, clinical and experimental research
researchProduct

Stratified Care vs Step Care Strategies for Migraine

2000

ContextVarious guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.ObjectiveTo compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.Design and SettingRandomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical cen…

AdultMalemedicine.medical_specialtyMetoclopramideMigraine DisordersPopulationZolmitriptanSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessHumansMedicineeducationOxazolidinonesAspirineducation.field_of_studyAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialMigraineCritical PathwaysPhysical therapyDopamine AntagonistsFemalebusinessmedicine.drugJAMA
researchProduct

Current practice of hepatitis C treatment in Southern Italy.

2010

Abstract Background Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy. Aim To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings. Patients and methods A prospective study enrolling over a 6-month period (February–July 2009) all consecutive anti-HCV positive subjects initially referred (naive patients) to 12 liver units in Southern Italy for HCV treatment. Results Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated…

AdultMalemedicine.medical_specialtyMultivariate analysisHepatitis C virusAlcohol abuseHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene GlycolsTreatment RefusalSex FactorsInternal medicineRibavirinHumansMedicineProspective StudiesProspective cohort studyAgedHepatologybusiness.industryGastroenterologyAntiviral therapyInterferon-alphaAlanine TransaminaseHepatitis CHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsAlcoholismTreatment OutcomeItalyCurrent practiceImmunologyHCVHcv treatmentEducational StatusRNA ViralFemalebusiness
researchProduct

Functional results after operative treatment of olecranon fractures.

2004

In a retrospective, nonrandomized study, we reviewed our experience with the operative treatment of olecranon fractures to find out which factors correlate with subjective complaints and functional outcome. A total of 95 consecutive olecranon fractures were operatively treated in our level I trauma institution between March 1, 1992 and March 1, 2000. Medical charts and radiographs of all patients were evaluated. Three patients died, 23 were lost to follow-up. Fifty-eight of 69 available patients (84.0%) were reviewed clinically and/or radiologically after a mean time interval of 36 months. Fracture type, fracture classification, associated lesions, technical correctness of osteosynthesis, a…

AdultMalemedicine.medical_specialtyOlecranonElbowBone healingFracture Fixation InternalFracture fixationElbow JointmedicineHumansDevice RemovalAgedRetrospective StudiesAged 80 and overOsteosynthesisbusiness.industryTension band wiringRetrospective cohort studyGeneral MedicineRecovery of FunctionMiddle Agedmedicine.diseaseUlna FracturesSurgeryRadiographymedicine.anatomical_structureTreatment OutcomeOlecranon fractureSurgeryFemalebusinessElbow InjuriesActa chirurgica Belgica
researchProduct

Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation

2019

The replication kinetics of nonpathogenic anelloviruses belonging to the Alphatorquevirus genus (such as torque teno virus) might reflect the overall state of posttransplant immunosuppression. We analyzed 221 kidney transplant (KT) recipients in whom plasma alphatorquevirus DNA load was quantified by real-time polymerase chain reaction at baseline and regularly through the first 12 posttransplant months. Study outcomes included posttransplant infection and a composite of opportunistic infection and/or de novo malignancy (immunosuppression-related adverse event [iRAE]). Alphatorquevirus DNA loads at month 1 were higher among patients who subsequently developed posttransplant infection (P  = …

AdultMalemedicine.medical_specialtyOpportunistic infectionmedicine.medical_treatment030230 surgeryAnelloviridaeGastroenterologylaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Prospective StudiesAdverse effectPolymerase chain reactionKidney transplantationAgedTransplantationbusiness.industryHazard ratioImmunosuppressionMiddle Agedmedicine.diseaseKidney TransplantationConfidence intervalDNA ViralFemalebusinessViral loadImmunosuppressive AgentsAmerican Journal of Transplantation
researchProduct

FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2005

Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m 2 on day 1 with LV5FU2 regimen (LV at 100mg/m 2 administered as a 2-hour infusion before FU at 400mg/m 2 as an intravenous bolus injection, and FU at 600mg/m 2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in th…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsCombination therapyColorectal cancerLeucovorinGastroenterologyFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryCarcinomaLiver NeoplasmsHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

2006

Background The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer. Patients and methods Eighty-one chemotherapy-naive patients entered in this randomized phase II trial of the GOIM (protocol no. 2301). Patients were randomized to receive FOLFIRI regimen (arm A): irinotecan 180 mg/m2 on day 1 with LV5FU2 regimen (LV at 100 mg/m2 administered as a 2-h infusion before FU at 400 mg/m2 as an intravenous bolus injection, and FU at 600 mg/m2 as a 22-h infusion immediately after 5-FU bolus injection on day 1 and 2); or FOLFIRI plus celecoxib 400 mg twice daily for 14 days (arm B). Both…

AdultMalemedicine.medical_specialtyOrganoplatinum CompoundsLeucovorinPhases of clinical researchIrinotecanGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsFOLFIRI RegimenHumansMedicineAgedSulfonamidesbusiness.industryHematologyMiddle AgedSurgeryOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyCelecoxibFluorouracilCelecoxibFOLFIRIPyrazolesCamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Spirituality in patients with advanced illness: The role of symptom control, resilience and social network.

2015

In this study, we analyzed the relationships among clinical, emotional, social, and spiritual dimensions of patients with advanced illness. It was a cross-sectional study, with a sample of 108 patients in an advanced illness situation attended by palliative care teams. Statistically significant correlations were found between some dimensions of spirituality and poor symptomatic control, resiliency, and social support. In the structural model, three variables predicted spirituality: having physical symptoms as the main source of discomfort, resiliency, and social support. This work highlights the relevance of the relationships among spirituality and other aspects of the patient at the end o…

AdultMalemedicine.medical_specialtyPalliative careAdolescentmedia_common.quotation_subjectEmotions03 medical and health sciencesSocial supportYoung Adult0302 clinical medicineSpiritualitymedicineHumansTerminally IllIn patientSymptom controlSpirituality030212 general & internal medicinePsychiatryApplied Psychologymedia_commonAgedAged 80 and overTerminal CareSocial networkbusiness.industryPalliative CareSocial SupportMiddle AgedResilience PsychologicalCross-Sectional Studies030220 oncology & carcinogenesisFemalePsychological resiliencePsychologybusinessClinical psychologyJournal of health psychology
researchProduct

Assessing Somatic, Psychosocial, and Spiritual Distress of Patients with Advanced Cancer

2012

Objective: For adequate distress assessment in palliative care, we developed a screening evaluation tool. Methods: Proven methods of scale construction led to a 53-item pilot form of the Advanced Cancer Patients’ Distress Scale (ACPDS). We used Hornheide Questionnaire (HQ), Palliative Outcome Scale (POS), and Minimal Documentation System (MIDOS) for validation. Advanced cancer patients (N = 168) from 3 centers for palliative medicine (aged 23-89, 51% female) filled out the questionnaire. Results: With a principal component analysis (PCA), we extracted 5 distress scales (emotional reactions/physical restrictions, communication deficits, negative social reactions, pain, and gastrointestinal s…

AdultMalemedicine.medical_specialtyPalliative carePsychometricsGastrointestinal DiseasesPsychological interventionPainSpiritual distressYoung AdultGermanyNeoplasmsSickness Impact ProfileSurveys and QuestionnairesActivities of Daily LivingmedicineHumansTerminally IllPsychological testingSex DistributionAgedAged 80 and overbusiness.industryPalliative CareReproducibility of ResultsCancerGeneral MedicineMiddle Agedmedicine.diseaseDistressDyspneaScale (social sciences)Physical therapyFemalebusinessPsychosocialAmerican Journal of Hospice and Palliative Medicine®
researchProduct